| Schedule of segment revenue and segment net income from operations |
The following table illustrates segment revenue and segment net income from operations, including significant expense items reviewed by the CODM for the three months ended March 31, 2026. | | Pharmaceutical Products Distribution | | | Real Estate Development | | | Total | | Revenue | | $ | 596,176 | | | $ | 22,500 | | | $ | 618,676 | | | | | | | | | | | | | | | Less: | | | | | | | | | | | | | Cost of revenues - product sales | | | 466,004 | | | | - | | | | 466,004 | | Cost of revenues - rent | | | - | | | | 7,500 | | | | 7,500 | | General and administrative[1] | | | 356,414 | | | | 8,125 | | | | 364,539 | | Depreciation and amortization | | | 6,124 | | | | 2,448 | | | | 8,572 | | | | | | | | | | | | | | | Segment net income (loss) from operations | | $ | (232,366 | ) | | $ | 4,427 | | | $ | (227,939 | ) |
The following table illustrates segment revenue and segment net income from operations, including significant expense items reviewed by the CODM for the nine months ended March 31, 2026. | | Pharmaceutical Products Distribution | | | Real Estate Development | | | Total | | Revenue | | $ | 1,626,982 | | | $ | 67,500 | | | $ | 1,694,482 | | | | | | | | | | | | | | | Less: | | | | | | | | | | | | | Cost of revenues - product sales | | | 1,256,774 | | | | - | | | | 1,256,774 | | Cost of revenues - rent | | | - | | | | 23,775 | | | | 23,775 | | General and administrative[1] | | | 1,192,069 | | | | 24,375 | | | | 1,216,444 | | Depreciation and amortization | | | 18,373 | | | | 7,077 | | | | 25,450 | | | | | | | | | | | | | | | Segment net income (loss) from operations | | $ | (840,234 | ) | | $ | 12,273 | | | $ | (827,961 | ) |
|
| Schedule of reconciliation of segment operating income to net income before taxes |
The following table illustrates the reconciliation of segment operating income to net income before taxes for the three months ended March 31, 2026. | | March 31, 2026 | | Segment loss from operations | | $ | (227,939 | ) | | | | | | Reconciling items | | | | | Interest expense | | | (12,725 | ) | | | | | | Net income (loss) from continued operations before income taxes | | $ | (240,664 | ) |
The following table illustrates the reconciliation of segment operating income to net income before taxes for the three months ended March 31, 2026. | | March 31, 2026 | | Segment loss from operations | | $ | (827,961 | ) | | | | | | Reconciling items | | | | | Interest Expense | | | (39,290 | ) | Loss on exchange of Series C & D preferred shares | | | (241,918 | ) | | | | | | Net income (loss) from continued operations before income taxes | | $ | (1,109,169 | ) |
|